TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10418538

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 471

Group type: COMPARATOR
Intervention: Imipramine hydrochloride
Number of subjects: 471

Group type: COMPARATOR
Intervention: Desipramine hydrochloride
Number of subjects: 471
Study: 8614301

Group type: EXPERIMENTAL
Intervention: Seal/Cod Liver Oil (CLO)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Whale Oil
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Seal Oil
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Cod Liver Oil (CLO)
Number of subjects: 134

Group type: COMPARATOR
Intervention: No Oil (Control)
Number of subjects: 134
Study: 1704879

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 6789720

Group type: EXPERIMENTAL
Intervention: 2% cromolyn solution
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31622643

Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 30971750

Group type: EXPERIMENTAL
Intervention: Apple juice treated with invertase, glucose oxidase/catalase (glucose 0.05 g; gluconate 18.2 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated apple juice (free glucose 8.5 g; bound glucose 6.7 g; gluconate below detection limit)
Number of subjects: 30
Study: 27718013

Group type: EXPERIMENTAL
Intervention: L-DOPA administration
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 28
Study: 25956354

Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy (BBAT)
Number of subjects: 15
Study: 23565815

Group type: EXPERIMENTAL
Intervention: 1.7 g of omega-3 fatty acids (O3) per day for 4 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Safflower oil placebo for 4 weeks
Number of subjects: 57
Study: 21150665

Group type: EXPERIMENTAL
Intervention: Bryan disc arthroplasty
Number of subjects: 46

Group type: COMPARATOR
Intervention: ProDisc-C arthroplasty
Number of subjects: 46
Study: 19657503

Group type: EXPERIMENTAL
Intervention: Dance and movement teaching method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional pharmacy lecture and PowerPoint slides
Number of subjects: 0
Study: 17334533

Group type: EXPERIMENTAL
Intervention: Olanzapine (mean dosage: 13.6 +/- 6.9 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Haloperidol (mean dosage: 5.8 +/- 3.8 mg)
Number of subjects: 12
Study: 15201559

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 2.5 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nifedipine LA 30 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 24
Study: 11296176

Group type: EXPERIMENTAL
Intervention: Nasal noninvasive mechanical ventilation (NIMV)
Number of subjects: 36
Study: 9336752

Group type: EXPERIMENTAL
Intervention: Continuous vacuum extraction (n = 164)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Intermittent vacuum extraction (n = 158)
Number of subjects: 322
Study: 7515345

Group type: EXPERIMENTAL
Intervention: Energy-dense porridge made liquid by adding amylase-rich flour from germinated wheat (test diet)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Unaltered thick porridge of similar energy density (control 1 diet)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Porridge made liquid with addition of water to have the same viscosity as the test diet but of lower energy (control 2 diet)
Number of subjects: 78
Study: 3270664

Group type: EXPERIMENTAL
Intervention: PT-01 applied site (T)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo-applied site (P)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control site (C)
Number of subjects: 147
Study: 28671552

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable vascular scaffold (BVS)
Number of subjects: 5583

Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stent (EES)
Number of subjects: 5583
Study: 27004411

Group type: EXPERIMENTAL
Intervention: Isoflavone-enriched soy extract (117.4 mg/day isoflavone aglycone equivalents) for 12 weeks
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 25341140

Group type: EXPERIMENTAL
Intervention: Nephrographic phase MDCT urography
Number of subjects: 121

Group type: COMPARATOR
Intervention: Pyelographic phase MDCT urography
Number of subjects: 121
Study: 23528159

Group type: EXPERIMENTAL
Intervention: V + C (oral vinorelbine at 80 mg/m², then 60 mg/m² after first cycle, and capecitabine at 1,000 mg/m² bid from days 1 to 14)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: V↔C (oral vinorelbine weekly and capecitabine at 1,000 mg/m² bid from days 1 to 14)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: D + C (docetaxel at 75 mg/m² on day 1 and capecitabine at 1,000 mg/m² bid from days 1 to 14)
Number of subjects: 139
Study: 19952980

Group type: EXPERIMENTAL
Intervention: GARDASIL (0.5 mL dose at day 1, month 2, and month 6) with REPEVAX (0.5 mL dose on day 1 or month 1)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: REPEVAX administered concomitantly with GARDASIL
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Concomitant administration of GARDASIL and REPEVAX
Number of subjects: 843
Study: 18584876

Group type: EXPERIMENTAL
Intervention: Adjunctive treatment with 4 mg triamcinolone acetonide (TA) injected into the silicone-filled vitreous cavity
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no adjunctive treatment)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Adjunctive treatment with 4 mg triamcinolone acetonide (TA)
Number of subjects: 75
Study: 15801919

Group type: EXPERIMENTAL
Intervention: Prolonged lamivudine treatment
Number of subjects: 85
Study: 11821454

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (100 microg/kg per chemotherapy cycle)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Filgrastim (5 microg/kg/d)
Number of subjects: 310
Study: 10518177

Group type: EXPERIMENTAL
Intervention: 5-HT antagonist metergoline
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8834843

Group type: EXPERIMENTAL
Intervention: Bacterial meningitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacterial meningitis (fatal outcome)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lymphocytic meningitis
Number of subjects: 0
Study: 2202549

Group type: EXPERIMENTAL
Intervention: Controlled-release indomethacin tablets, 75 mg given at night
Number of subjects: 80

Group type: COMPARATOR
Intervention: Immediate-release indomethacin capsules, 75 mg given 3-times daily
Number of subjects: 80
Study: 7247635

Group type: EXPERIMENTAL
Intervention: Food coloring
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29023829

Group type: EXPERIMENTAL
Intervention: Domagrozumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allometric approaches for dosing per body weight
Number of subjects: 0
Study: 27491736

Group type: EXPERIMENTAL
Intervention: sub-CIS <2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: sub-CIS=2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: sub-CIS=2 plus good revascularization
Number of subjects: 50
Study: 24634462

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) - 15 mg/16 hr nicotine patches
Number of subjects: 33

Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 33
Study: 23664370

Group type: EXPERIMENTAL
Intervention: Hypothermia (rapidly cooled to 32-33°C for 48-72 hours, then rewarmed by 0.5-1.0°C every 12-24 hours)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Normothermia (maintained at 36.5-37.5°C)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 77

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 77
Study: 20378563

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg/m²
Number of subjects: 325

Group type: COMPARATOR
Intervention: Prednisolone 60 mg/m²
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 325

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 325
Study: 19026890

Group type: EXPERIMENTAL
Intervention: Smear layer present (smear [+]) - irrigated with NaOCl (5.25%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Smear layer absent (smear [‐]) - irrigated with EDTA (17%) and NaOCl (5.25%)
Number of subjects: 50
Study: 16925285

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac perioperatively continued for 24 hours postoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: Remifentanil intraoperatively as part of balanced anesthesia
Number of subjects: 50
Study: 12538377

Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg i.v.
Number of subjects: 40
Study: 10987706

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (2 g/1 g) administered intravenously every 6 h
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cefoxitin (2 g) administered intravenously every 6 h
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Patients with histories of injection drug abuse
Number of subjects: 96

Group type: COMPARATOR
Intervention: Patients without histories of injection drug abuse
Number of subjects: 96
Study: 8605592

Group type: EXPERIMENTAL
Intervention: Didanosine (400 mg/day) plus Zidovudine (500 mg/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Dideoxicytidine (2.25 mg/day) plus Zidovudine (500 mg/day)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Didanosine plus Zidovudine
Number of subjects: 67
Study: 1396726

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (trimethoprim-sulfamethoxazole) 40 mg/kg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (trimethoprim-sulfamethoxazole) 120 mg/kg/day
Number of subjects: 24
Study: 3933261

Group type: EXPERIMENTAL
Intervention: Midthoracic epidural morphine (5 mg injected at the end of the operation and subsequently three times a day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lumbar epidural morphine (5 mg injected at the end of the operation and subsequently three times a day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midthoracic epidural morphine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lumbar epidural morphine
Number of subjects: 30
Study: 31420883

Group type: EXPERIMENTAL
Intervention: 3 hr sitting with 10 calf raises every 10 min (CALF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3 hr sitting without intermittent calf raises (CON)
Number of subjects: 20
Study: 29576304

Group type: EXPERIMENTAL
Intervention: dTap-IPVB (Boostrix-IPV, GSK)
Number of subjects: 387

Group type: COMPARATOR
Intervention: dTap-IPVR (Repevax, Sanofi Pasteur)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: dTap-IPVB
Number of subjects: 387

Group type: COMPARATOR
Intervention: dTap-IPVR
Number of subjects: 387
Study: 27857632

Group type: EXPERIMENTAL
Intervention: Multimodal exercise-based physical therapy with whole-body vibration (WBV) therapy plus traction (IBI group)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Multimodal exercise-based physical therapy without WBV therapy plus traction (FOTO group)
Number of subjects: 125
Study: 25849961

Group type: EXPERIMENTAL
Intervention: Conjunctival autograft (CAG) with fibrin glue
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Amniotic membrane graft (AMG) with fibrin glue
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (CAG)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (AMG)
Number of subjects: 65
Study: 22849580

Group type: COMPARATOR
Intervention: Docetaxel at 60 mg/m2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel at 60 mg/m2 plus bevacizumab at 15 mg/kg
Number of subjects: 0
Study: 20417879

Group type: EXPERIMENTAL
Intervention: Nutrition Education Program (NEP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 18683667

Group type: EXPERIMENTAL
Intervention: On-pump surgery (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Off-pump surgery (n=20)
Number of subjects: 40
Study: 15911947

Group type: EXPERIMENTAL
Intervention: IV diltiazem 0.25 mg/kg (maximum 25 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metoprolol 0.15 mg/kg (maximum 10 mg)
Number of subjects: 40
Study: 12888588

Group type: EXPERIMENTAL
Intervention: ABLC 3 mg/kg/day for 5 days (ABLC-5)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ABLC 3 mg/kg/day for 10 days (ABLC-10)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Meglumine antimoniate 20 mg Sbv/kg/day for 28 days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Meglumine antimoniate
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ABLC groups
Number of subjects: 57
Study: 10574596

Group type: EXPERIMENTAL
Intervention: Uterine Leiomyosarcomas (ULMS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Extrauterine Leiomyosarcomas (EULMS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Uterine and Extrauterine Leiomyomas (LM)
Number of subjects: 40
Study: 8669720

Group type: EXPERIMENTAL
Intervention: Thrombosis patients (3)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Hemorrhage patient (1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Healthy subject (1)
Number of subjects: 5
Study: 1706248

Group type: EXPERIMENTAL
Intervention: Stereoscopic stimuli (dynamic random-dot stereograms presented as a stereoscopic checkerboard pattern)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Contrast stimuli (conventional 2-dimensional checkerboard reversal stimulus)
Number of subjects: 13
Study: 6729152

Group type: EXPERIMENTAL
Intervention: etidocaine 1%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.75%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5%
Number of subjects: 20
Study: 30636691

Group type: EXPERIMENTAL
Intervention: RFM visible during training
Number of subjects: 400

Group type: COMPARATOR
Intervention: RFM masked during training (Control)
Number of subjects: 400
Study: 29089207

Group type: EXPERIMENTAL
Intervention: Massage with carrier oil
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Massage with aromatherapy oil
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard nursing care only
Number of subjects: 284
Study: 26897384

Group type: EXPERIMENTAL
Intervention: Axillary exclusion technique
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional procedure
Number of subjects: 64
Study: 25250691

Group type: EXPERIMENTAL
Intervention: Walking across a HIGH plank (anxiety-inducing condition)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Walking across a LOW plank (less anxiety-inducing condition)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Walking across a HIGH plank (anxiety-inducing condition) in OFF state
Number of subjects: 31
Study: 20423278

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Yuzpe regimen (high dose combined oral contraceptive pills)
Number of subjects: 337
Study: 15802944

Group type: EXPERIMENTAL
Intervention: Attachment measures including the Relationship Questionnaire, Relationship Style Questionnaire, and Experiences in Close Relationships inventory.
Number of subjects: 99
Study: 12837046

Group type: EXPERIMENTAL
Intervention: Policosanol (10 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lovastatin (20 mg/day)
Number of subjects: 36
Study: 9396545

Group type: EXPERIMENTAL
Intervention: Open fetal surgery for repair of CDH
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard postnatal care
Number of subjects: 11
Study: 8122720

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 3282868

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (900 mg daily for 14 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Piroxicam (40 mg daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall assessment by physician
Number of subjects: 80
Study: 11228804

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study: 30836984

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (PS) and Unconditional Cash Transfer (UCT) with Health Education (HE)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfer (UCT) with Health Education (HE)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Comparison arm
Number of subjects: 588
Study: 29433668

Group type: EXPERIMENTAL
Intervention: Comprehensive radio campaign
Number of subjects: 14

Group type: COMPARATOR
Intervention: No radio media campaign (Control)
Number of subjects: 14
Study: 26865444

Group type: EXPERIMENTAL
Intervention: Self-apposing, sirolimus-eluting STENTYS stent
Number of subjects: 152

Group type: COMPARATOR
Intervention: Zotarolimus-eluting balloon-expandable stent
Number of subjects: 152
Study: 24457472

Group type: EXPERIMENTAL
Intervention: Arterial infusion of p53 gene (Gendicine, 10vp) combined with hydroxycamptothecin (20 mg), once a week for 3 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Arterial infusion with hydroxycamptothecin (20 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Arterial infusion of p53 gene (Gendicine)
Number of subjects: 48
Study: 22237855

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typical antipsychotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 19931427

Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg/day (e-group, N=24)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Treatment as usual (c-group, N=24)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg/day (e-group)
Number of subjects: 48
Study: 17090635

Group type: EXPERIMENTAL
Intervention: School-based intervention consisting of health, nutrition, and exercise classes plus an aerobic exercise program
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (studied twice without receiving the intervention)
Number of subjects: 73
Study: 15203786

Group type: EXPERIMENTAL
Intervention: Nicotine skin patches (21 mg/24 hr)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mecamylamine (10 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of nicotine skin patches and mecamylamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching to denicotinized cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching to cigarettes with different menthol flavor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ventilated-filter (low tar and nicotine) cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mentholated cigarettes for menthol smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonmentholated cigarettes for nonmenthol smokers
Number of subjects: 0
Study: 11254917

Group type: EXPERIMENTAL
Intervention: Fenofibrate (FEN) 200 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study: 9736816

Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5-10 mg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Doxazosin (2-8 mg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combination of cilazapril and doxazosin (half doses)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg) added after initial treatments
Number of subjects: 76
Study: 8047423

Group type: EXPERIMENTAL
Intervention: 2% nitroglycerin ointment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 80
Study: 2929853

Group type: EXPERIMENTAL
Intervention: Ivermectin (50, 100, 150, or 200 micrograms/kg body wt); 55 recipients of 100 or 200 micrograms/kg doses received a second identical dose the next day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 200
Study: 29550406

Group type: EXPERIMENTAL
Intervention: Inactivated whole-cell oral cholera vaccine (OCV)
Number of subjects: 204700

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 204700
Study: 28963124

Group type: EXPERIMENTAL
Intervention: PULSE (40g whey protein as hourly drinks, 4g per drink)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BOLUS (40g whey protein as two boluses, 28g at 0h and 12g at 7h)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LL‐RE (light-load resistance exercise, leg extensions, 10 sets of 36 repetitions at 16% 1RM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (hourly isocaloric maltodextrin drinks)
Number of subjects: 30
Study: 26298694

Group type: EXPERIMENTAL
Intervention: Pressure bladder indicator
Number of subjects: 130

Group type: COMPARATOR
Intervention: Epidural pressure measurement
Number of subjects: 130

Group type: COMPARATOR
Intervention: Bladder working pressure measurement
Number of subjects: 130
Study: 22664478

Group type: EXPERIMENTAL
Intervention: FOLFOX4/PTK/ZK
Number of subjects: 85

Group type: COMPARATOR
Intervention: FOLFOX4/placebo
Number of subjects: 85
Study: 21621727

Group type: EXPERIMENTAL
Intervention: Custom-made shoe orthotics for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-list control group (no treatment for 6 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Custom-made shoe orthotics for 12 weeks (after initial 6 weeks)
Number of subjects: 50
Study: 19337169

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 53
Study: 16489468

Group type: EXPERIMENTAL
Intervention: 3.0 T MR angiography
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional catheter angiography (CCA)
Number of subjects: 27
Study: 15192630

Group type: EXPERIMENTAL
Intervention: Surfactant administration (Survanta, Ross Laboratories, Columbus, Ohio)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Expectant management (control group)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Surfactant administration
Number of subjects: 132
Study: 10701031

Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen 100 mg (two doses: one at the end of surgery and one 12 hours postoperatively)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9347201

Group type: EXPERIMENTAL
Intervention: Flumazenil (3 mg infused intravenously)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline (placebo, infused intravenously)
Number of subjects: 13